Drug Profile
Pegfilgrastim biosimilar - USV
Alternative Names: Grasustek; Neulasta biosimilar; PEG G-CSF biosimilar - USV; Pegylated filgrastim biosimilar - USV; Pegylated-granulocyte colony stimulating factor biosimilar - USVLatest Information Update: 20 Apr 2022
Price :
$50
*
At a glance
- Originator USV
- Class Antineoplastics; Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte colony stimulating factor receptor agonists; Granulocyte colony-stimulating factor replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Marketed Neutropenia
Most Recent Events
- 20 Apr 2022 Launched for Neutropenia in Liechtenstein, Iceland, Norway, European Union (SC) prior to April 2022 (USV website, April 2022)
- 20 Apr 2022 Registered for Neutropenia in India (SC), prior to April 2022 (USV website, April 2022)
- 20 Apr 2022 USV plans a BPD meeting with the US FDA, prior to April 2022 (USV website, April 2022)